

AMENDMENT TO THE CLAIMS

1.-42. (Cancelled) .

43. (Currently Amended) A vector for expression of GAD65 in cells of the central nervous system of a subject comprising:

an adeno-associated viral vector;

a tissue specific promoter operably linked to a nucleotide sequence encoding GAD65;

and

a post-transcriptional regulatory element, wherein the post-transcriptional regulatory element is the woodchuck hepatitis post-transcriptional regulatory element.

44.-45 (Cancelled.)

46. (Original) The vector of claim 43, wherein the promoter is the neuron specific enolase (NSE) promoter.

47.-48 (Cancelled.)

49. (Currently Amended) The vector of claim 43, wherein the promoter is ~~the~~ a cytomegalovirus enhancer/chicken-actin (CBA) promoter.

50. (Previously Presented) The vector of claim 43 wherein the GAD65 is human GAD65.

51. (Currently Amended) The vector of claim 43, wherein the vector is formulated in a pharmaceutical composition for *in vivo* administration capable of transducing ~~a cell~~ cells of the central nervous system (CNS) of the subject ~~upon *in vivo* administration of the vector.~~

52. (Previously Presented) The vector of claim 51 wherein the GAD65 is human GAD65.

53. (Previously Presented) The vector of claim 51 wherein the subject is a mammal.

54. (Previously Presented) The vector of claim 43, wherein the vector is capable of transducing a primary mammalian neural cell.
55. (Previously Presented) The vector of claim 53 wherein the subject is a primate.